Assenagon Asset Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Assenagon Asset Management’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-346,296	Closed	-$1.01M	–	1612
2021 Q3	$1.01M	Buy	346,296 +292,452	+543%	+$972K	﹤0.01%	905
2021 Q2	$188K	Buy	53,844 +18,736	+53%	+$64.3K	﹤0.01%	1147
2021 Q1	$120K	Sell	35,108 -211,427	-86%	-$4M	﹤0.01%	1172
2020 Q4	$4.73M	Buy	246,535 +74,900	+44%	+$1.16M	0.02%	361
2020 Q3	$2.31M	Buy	171,635 +119,435	+229%	+$3.38M	0.01%	550
2020 Q2	$2.21M	Buy	+52,200	New	+$1.69M	0.01%	568

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Assenagon Asset Management's ODT Position: Q4 2021 in Review

Assenagon Asset Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 346,296 shares — an estimated $1.01M sold.

Assenagon Asset Management first reported a position in ODT in Q2 2020 and held it in 6 quarters. The position peaked at $4.73M in Q4 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

Assenagon Asset Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Assenagon Asset Management sold 346,296 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $1.01M.
Assenagon Asset Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Assenagon Asset Management's Odonate Therapeutics, Inc. Common Stock position peaked at $4.73M in Q4 2020.
50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Assenagon Asset Management's 13F filing for Q4 2021, filed 1 Feb 2022.